Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors

Cheng Liu, President and Chief Scientific Officer of Estrella Immunopharma

“On behalf of the Board, I am delighted to welcome Cynthia to Estrella”

Cheng Liu, President and Chief Scientific Officer of Estrella Immunopharma

“Cynthia brings a rare combination of public-company leadership, hands-on experience in cell and gene therapy development and manufacturing, and a strong track record of building strategic and financial partnerships.”

Cheng Liu, President and Chief Scientific Officer of Estrella Immunopharma

“As Estrella enters its next phase of clinical development, the Board and I are confident that she is the right leader to build on the progress we have made with EB103 and the ARTEMIS® platform.”

Cheng Liu, President and Chief Scientific Officer of Estrella Immunopharma

“I look forward to working closely with Cynthia to ensure a seamless transition.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“I am absolutely delighted to join Estrella Immunopharma at such a pivotal moment in the Company’s evolution”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“Throughout my career, I have been driven by the opportunity to translate groundbreaking science into meaningful, life-changing therapies for patients.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“What attracted me to Estrella is the compelling combination of differentiated science, strong early clinical validation and the extraordinary potential of the ARTEMIS® platform to redefine what is possible with engineered T-cell therapies.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“While CAR-T therapies have transformed the treatment landscape for certain cancers, significant unmet needs remain, particularly with respect to response durability, treatment-related toxicity and access for patients who may not be eligible for currently marketed therapies.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“ARTEMIS® represents an exciting opportunity to address these limitations, with the potential to deliver deeper and more durable responses and improved tolerability.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“The early clinical results are encouraging, and I believe we have an exceptional foundation upon which to build.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“Equally exciting is the opportunity to extend this innovative technology beyond hematologic cancers into additional oncology indications and autoimmune diseases, where more effective, durable and potentially transformative treatment options are desperately needed.”

Cynthia Pussinen, Chief Executive Officer and Chairperson of the Board of Estrella Immunopharma

“I am honored to work alongside Estrella’s talented scientists, clinicians, partners and Board to advance these promising therapies, accelerate clinical development, build long-term shareholder value and, most importantly, bring new hope to patients and families around the world.”